

# David J Pinato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4085273/publications.pdf>

Version: 2024-02-01

190  
papers

8,114  
citations

66343

42  
h-index

69250

77  
g-index

193  
all docs

193  
docs citations

193  
times ranked

9475  
citing authors

#	ARTICLE	IF	CITATIONS
1	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
2	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	27.6	643
3	Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1774.	7.1	396
4	A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). <i>British Journal of Cancer</i> , 2012, 106, 1439-1445.	6.4	322
5	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 338-346.	3.7	299
6	PD-L1. <i>Journal of Clinical Pathology</i> , 2018, 71, 189-194.	2.0	218
7	A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). <i>Journal of Hepatology</i> , 2012, 57, 1013-1020.	3.7	164
8	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	5.9	154
9	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	9.4	151
10	Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. <i>British Journal of Cancer</i> , 2014, 110, 1930-1935.	6.4	139
11	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	1.6	135
12	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
13	Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3323.	2.4	131
14	Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 587-594.	1.1	128
15	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
16	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
17	A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers. <i>PLoS ONE</i> , 2012, 7, e51395.	2.5	102
18	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92

#	ARTICLE	IF	CITATIONS
19	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	1.3	91
20	Alterations of Choline Phospholipid Metabolism in Endometrial Cancer Are Caused by Choline Kinase Alpha Overexpression and a Hyperactivated Deacylation Pathway. <i>Cancer Research</i> , 2014, 74, 6867-6877.	0.9	87
21	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP- $\beta$ , in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3936-3946.	7.0	86
22	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	2.8	81
23	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
24	Antibiotic therapy and outcome from immune-checkpoint inhibitors. , 2019, 7, 287.		77
25	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. <i>Immunology</i> , 2020, 159, 167-177.	4.4	75
26	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	7.1	74
27	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	10.7	73
28	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
29	Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. <i>British Journal of Cancer</i> , 2019, 120, 1033-1036.	6.4	66
30	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
31	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: Implications for immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1213934.	4.6	65
32	Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 2258-2270.	7.3	64
33	Programmed cell death ligands expression in pheochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior. <i>Oncolmmunology</i> , 2017, 6, e1358332.	4.6	60
34	An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. <i>Translational Research</i> , 2012, 160, 146-152.	5.0	59
35	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409.	3.7	59
36	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020, 12, 1841.	3.7	58

#	ARTICLE	IF	CITATIONS
37	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Reports, 2021, 3, 100347.	4.9	57
38	The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver International, 2019, 39, 2008-2023.	3.9	56
39	Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treatment Reviews, 2013, 39, 153-160.	7.7	53
40	Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. Clinical Gastroenterology and Hepatology, 2015, 13, 1204-1208.e2.	4.4	53
41	Retinoic Acid Receptor $\alpha$ Is Downregulated in Hepatocellular Carcinoma and Cirrhosis and Its Expression Inhibits Myosin $\alpha$ -Driven Activation and Durotoxin in Hepatic Stellate Cells. Hepatology, 2019, 69, 785-802.	7.3	50
42	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	7.1	50
43	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncology, The, 2022, 23, 865-875.	10.7	50
44	Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. European Journal of Cancer, 2019, 116, 56-66.	2.8	48
45	Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. Hepatology, 2021, 74, 483-490.	7.3	48
46	On $\alpha$ -target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi $\alpha$ -centre, prospective study. Alimentary Pharmacology and Therapeutics, 2017, 45, 1146-1155.	3.7	47
47	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	3.7	47
48	Upregulation of C/EBP $\beta$ Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Clinical Cancer Research, 2021, 27, 5961-5978.	7.0	47
49	An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. British Journal of Cancer, 2014, 110, 115-122.	6.4	46
50	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
51	Peptide receptor radionuclide therapy for metastatic paragangliomas. Medical Oncology, 2016, 33, 47.	2.5	44
52	Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget, 2017, 8, 36161-36170.	1.8	44
53	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 2022, 14, 186.	3.7	44
54	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43

#	ARTICLE	IF	CITATIONS
55	Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 55-61.	3.3	42
56	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 301.	2.6	42
57	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	7.1	42
58	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	2.8	42
59	Immunohistochemical markers of the hypoxic response can identify malignancy in pheochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. <i>British Journal of Cancer</i> , 2013, 108, 429-437.	6.4	40
60	Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. <i>Liver Cancer</i> , 2021, 10, 240-248.	7.7	39
61	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
62	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5908-5917.	7.0	38
63	The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2013, 108, 621-628.	6.4	37
64	The albuminâ€“bilirubin grade improves hepatic reserve estimation postâ€“sorafenib failure: implications for drug development. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 714-722.	3.7	37
65	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	2.8	37
66	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	1.6	36
67	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
68	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	7.7	33
69	Qualification of tumour mutational burden by targeted nextâ€“generation sequencing as a biomarker in hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 192-203.	3.9	32
70	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 1391-1399.	1.2	32
71	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
72	Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. <i>Oncotarget</i> , 2016, 7, 44705-44718.	1.8	32

#	ARTICLE	IF	CITATIONS
73	Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 512-521.	6.4	31
74	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. <i>Liver Cancer</i> , 2019, 8, 281-294.	7.7	31
75	Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1270-1281.	3.7	30
76	Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, 488-494.	0.9	30
77	Gene of the month: <i>Axl</i>. <i>Journal of Clinical Pathology</i> , 2016, 69, 391-397.	2.0	30
78	Review article: delivering precision oncology in intermediate-stage liver cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1514-1523.	3.7	30
79	Hepatocellular carcinoma. <i>Aids</i> , 2017, 31, 603-611.	2.2	30
80	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
81	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 177-189.	3.7	29
82	De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management—Guidelines From the ILTS-SETH Consensus Conference. <i>Transplantation</i> , 2022, 106, e30-e45.	1.0	29
83	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. <i>Cancers</i> , 2020, 12, 3370.	3.7	28
84	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26
85	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 87.	3.0	25
86	An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials. <i>PLoS ONE</i> , 2014, 9, e83279.	2.5	25
87	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	2.8	24
88	Inflammation as a validated prognostic determinant in carcinoma of unknown primary site. <i>British Journal of Cancer</i> , 2014, 110, 208-213.	6.4	21
89	Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma. <i>Advances in Anatomic Pathology</i> , 2014, 21, 270-284.	4.3	21
90	Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. <i>Liver Cancer</i> , 2017, 6, 313-324.	7.7	21

#	ARTICLE	IF	CITATIONS
91	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
92	Evaluating the impact of COVID-19 on supportive care needs, psychological distress and quality of life in UK cancer survivors and their support network. European Journal of Cancer Care, 2021, 30, e13442.	1.5	21
93	The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. Annals of Translational Medicine, 2021, 9, 1034-1034.	1.7	21
94	The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2018, 47, 95-103.	3.7	20
95	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2022, 22, 253-264.	3.1	20
96	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. European Journal of Cancer, 2021, 148, 24-35.	2.8	19
97	Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Science Translational Medicine, 2021, 13, .	12.4	19
98	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European Journal of Cancer, 2022, 171, 64-74.	2.8	19
99	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	2.5	18
100	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 887-897.	3.7	17
101	TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene, 2016, 35, 2684-2686.	5.9	16
102	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
103	Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours. Neuroendocrinology, 2021, 111, 465-474.	2.5	15
104	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal of Cancer, 2021, 124, 407-413.	6.4	15
105	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110109.	3.2	15
106	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer, 2022, 128, 3067-3079.	4.1	15
107	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	4.4	14
108	Imatinib induced pyoderma gangrenosum. Journal of Postgraduate Medicine, 2013, 59, 244-245.	0.4	14

#	ARTICLE	IF	CITATIONS
109	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	6.3	14
110	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
111	Advanced age influences the dynamic changes in circulating C-reactive protein following injury. <i>Journal of Clinical Pathology</i> , 2013, 66, 695-699.	2.0	12
112	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
113	Systemic Inflammatory Response Is a Prognostic Marker in HIV-Infected Patients with Hepatocellular Carcinoma. <i>Oncology</i> , 2017, 93, 395-400.	1.9	11
114	Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma. <i>Medical Oncology</i> , 2018, 35, 53.	2.5	11
115	Management of Hepatocellular Cancer in the time of SARS-CoV-2. <i>Liver International</i> , 2020, 40, 1823-1825.	3.9	11
116	Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2137.	3.7	11
117	Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 908-910.	7.0	11
118	Clinical, Ethical and Financial Implications of Incidental Imaging Findings: Experience from a Phase I Trial in Healthy Elderly Volunteers. <i>PLoS ONE</i> , 2012, 7, e49814.	2.5	11
119	Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2078-2082.	1.6	11
120	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	2.8	11
121	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
122	Functional immune characterization of HIV-associated non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1486-1488.	1.2	10
123	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. <i>ESMO Open</i> , 2021, 6, 100123.	4.5	10
124	Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. , 2021, 9, e001519.		10
125	New Frontiers in the Medical Therapy of Hepatocellular Carcinoma. <i>Chemotherapy</i> , 2022, 67, 164-172.	1.6	10
126	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	1.9	10



#	ARTICLE	IF	CITATIONS
127	Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using <sup>18</sup> F-Fluorothymidine PET. Journal of Nuclear Medicine, 2020, 61, 1743-1748.	5.0	9
128	Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. European Journal of Cancer, 2022, 172, 199-208.	2.8	9
129	Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma. BMC Cancer, 2018, 18, 211.	2.6	8
130	Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.. Journal of Clinical Oncology, 2020, 38, 4585-4585.	1.6	8
131	Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer, 2023, 54, 420-432.	1.3	8
132	Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. Supportive Care in Cancer, 2021, 29, 7845-7854.	2.2	7
133	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq$ 50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. Thoracic Cancer, 2022, 13, 483-488.	1.9	7
134	Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. Expert Opinion on Investigational Drugs, 2022, 31, 681-691.	4.1	7
135	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatology Communications, 2022, 6, 1776-1785.	4.3	7
136	Cancer-related inflammation: An emerging prognostic domain in metastatic castration-resistant prostate carcinoma. Cancer, 2014, 120, 3272-3274.	4.1	6
137	Breaking Kuhn's paradigm in advanced hepatocellular carcinoma. Hepatology, 2018, 67, 1663-1665.	7.3	6
138	PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity. Immunotherapy, 2019, 11, 585-590.	2.0	6
139	Hepatitis B virus and lymphomagenesis: Novel insights into an occult relationship. Digestive and Liver Disease, 2012, 44, 235-238.	0.9	5
140	CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma. Journal of Clinical Pathology, 2013, 66, 256-259.	2.0	5
141	The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application. Liver International, 2015, 35, 2458-2465.	3.9	5
142	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110534.	3.2	5
143	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology and Oncology, 2022, 15, 9.	17.0	5
144	Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis.. Journal of Clinical Oncology, 2022, 40, 393-393.	1.6	5

#	ARTICLE	IF	CITATIONS
145	Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. <i>Medical Oncology</i> , 2016, 33, 114.	2.5	4
146	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	3.2	4
147	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
148	Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 4635-4638.	5.9	3
149	PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16131-e16131.	1.6	3
150	Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. <i>Cancers</i> , 2021, 13, 4232.	3.7	3
151	Programmed cell death (PD-1) ligands expression in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs): relationship with angiogenesis and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15658-e15658.	1.6	3
152	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3
153	An Unexpected Cause of Pulmonary Cannonball Lesion. <i>Journal of Thoracic Oncology</i> , 2014, 9, 259.	1.1	2
154	Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy. <i>Journal of Immunotherapy</i> , 2020, 43, 53-56.	2.4	2
155	Regorafenib therapy for hepatocellular carcinoma in a HIVâ€infected patient: A case report. <i>Liver Cancer International</i> , 2020, 1, 51-54.	1.3	2
156	Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancerâ€Reply. <i>JAMA Oncology</i> , 2020, 6, 587.	7.1	2
157	Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 445-445.	1.6	2
158	Impact of the G8 score on the outcome of a cohort of elderly patients with solid or hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12038-12038.	1.6	2
159	Abstract 485: Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study. , 2021, , .		2
160	Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma: a textbook outcome analysis. <i>Hpb</i> , 2022, 24, 664-671.	0.3	2
161	Development and validation of a therapyâ€independent hepatocellular carcinoma survival prediction score. <i>Liver Cancer International</i> , 0, , .	1.3	2
162	Reply to: â€Validating the ALBI grade: Its current and future use in HCC prognosticationâ€™. <i>Journal of Hepatology</i> , 2017, 66, 663-664.	3.7	1

#	ARTICLE	IF	CITATIONS
163	Therapeutic hierarchy in hepatocellular carcinoma: A dispute of evidence versus practice. <i>Liver International</i> , 2019, 39, 1622-1623.	3.9	1
164	Acceleration of interstitial lung disease induced by raltitrexed. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1241-1243.	0.9	1
165	Shifting paradigms in the systemic management of hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 883-885.	8.1	1
166	Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 207-208.	1.9	1
167	A pathway towards precision: Setting the agenda for <i>Liver Cancer International</i>. <i>Liver Cancer International</i> , 2020, 1, 5-5.	1.3	1
168	Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2643-2643.	1.6	1
169	Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1574-1574.	1.6	1
170	Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 515-516.	8.1	1
171	Mutations in circulating cell-free tumour DNA: Predictors of survival in hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 54-62.	1.3	1
172	Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 155, 315-316.	2.8	1
173	Pharmacological inhibition of Axl tyrosine kinase as a novel therapeutic strategy in hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15152-e15152.	1.6	1
174	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer (LC): Implications for immunotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11601-11601.	1.6	1
175	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4601-4601.	1.6	1
176	Post-registration experience of nivolumab (nivo) therapy in patients with advanced hepatocellular carcinoma (HCC): An international study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16677-e16677.	1.6	1
177	Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2022, 40, 399-399.	1.6	1
178	Editorial: dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1218-1219.	3.7	0
179	Editorial: a step forward in refining prognostication for patients with <scp>HIV</scp>-associated hepatocellular carcinoma – Authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 134-135.	3.7	0
180	Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, 139-140.	1.1	0

#	ARTICLE	IF	CITATIONS
181	Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2964-2966.	7.0	0
182	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16526-e16526.	1.6	0
183	Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4085-4085.	1.6	0
184	Tâ€œcell mediated responses against alphaâ€œfetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patientsâ€™ survival. <i>Liver Cancer International</i> , 2021, 2, 7-14.	1.3	0
185	SER-ONCOVID: Seroconversion in solid-tumor cancer patients after COVID-19 diagnosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2544-2544.	1.6	0
186	Prognostic subclassification of Intermediate Hepatocellular Carcinoma (I-HCC): a multicentre cohort study with propensity score analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15139-e15139.	1.6	0
187	An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12049-12049.	1.6	0
188	PD-L1 status and efficacy of immune check-point inhibitors (ICIs) in advanced cancer patients: A pooled analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15263-e15263.	1.6	0
189	Influence of antibiotic therapy (ATB) on oncological outcomes of metastatic non-small cell lung cancer (mNSCLC) patients treated with chemo-immunotherapy (CIT).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3080-3080.	1.6	0
190	Reply. <i>Hepatology</i> , 2022, 76, E82-E83.	7.3	0